XM does not provide services to residents of the United States of America.

In a first, FDA authorizes flavored e-cigarettes from Altria's NJOY for sale in the US



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>In a first, FDA authorizes flavored e-cigarettes from Altria's NJOY for sale in the US</title></head><body>

June 21 (Reuters) -The U.S. Food and Drug Administration authorized four of Altria's menthol e-cigarettes for sale in the country on Friday, making them the first ever flavored vapes the agency has permitted on the market.

The FDA has raised concerns about the risk of young people using e-cigarettes, particularly the more appealing flavored products.

In the past, the agency has rejected applications for flavored vapes from other manufacturers, including British American Tobacco BATS.L.

Marlboro maker Altria bought NJOY in March 2023 for about $2.75 billion in cash, renewing its bet on e-cigarettes as consumers adopt alternatives to traditional combustible cigarettes.

The FDA first began regulating e-cigarettes in August 2016 and has since made determinations on over 26 million applications for e-cigarette products. Including the flavored additions, it has authorized 27 e-cigarette products for sale in the U.S. to date.

"In this instance, the strength of evidence of benefits to adult smokers from completely switching to a less harmful product was sufficient to outweigh the risks to youth," said Matthew Farrelly, director of the Office of Science at the FDA's Center for Tobacco Products.

Altria did not immediately respond to a Reuters request for comment.

The FDA's authorization comes at a time when the U.S. government is reviewing a potential ban on menthol cigarettes. Anti-smoking groups argue that flavored cigarettes lure young people into smoking and contribute to disproportionate health burdens on Black communities.

Earlier this month, the FDA rescinded market denial orders issued in 2022 for four varieties of JUUL Lab's tobacco and menthol-flavored pods and its e-cigarette device.



Reporting by Juveria Tabassum; Editing by Pooja Desai

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.